scholarly journals Ischemic Heart Disease Selectively Modifies the Right Atrial Appendage Transcriptome

2021 ◽  
Vol 8 ◽  
Author(s):  
Severi Mulari ◽  
Arda Eskin ◽  
Milla Lampinen ◽  
Annu Nummi ◽  
Tuomo Nieminen ◽  
...  
Keyword(s):  
Heart Disease ◽  
Coronary Artery ◽  
Ischemic Heart Disease ◽  
Disease Severity ◽  
Bypass Surgery ◽  
Atrial Appendage ◽  
Right Atrial ◽  
Atrial Myocardium ◽  
Reflect Disease Severity ◽  
Right Atrial Appendage

Background: Although many pathological changes have been associated with ischemic heart disease (IHD), molecular-level alterations specific to the ischemic myocardium and their potential to reflect disease severity or therapeutic outcome remain unclear. Currently, diagnosis occurs relatively late and evaluating disease severity is largely based on clinical symptoms, various imaging modalities, or the determination of risk factors. This study aims to identify IHD-associated signature RNAs from the atrial myocardium and evaluate their ability to reflect disease severity or cardiac surgery outcomes.Methods and Results: We collected right atrial appendage (RAA) biopsies from 40 patients with invasive coronary angiography (ICA)-positive IHD undergoing coronary artery bypass surgery and from 8 patients ICA-negative for IHD (non-IHD) undergoing valvular surgery. Following RNA sequencing, RAA transcriptomes were analyzed against 429 donors from the GTEx project without cardiac disease. The IHD transcriptome was characterized by repressed RNA expression in pathways for cell–cell contacts and mitochondrial dysfunction. Increased expressions of the CSRNP3, FUT10, SHD, NAV2-AS4, and hsa-mir-181 genes resulted in significance with the complexity of coronary artery obstructions or correlated with a functional cardiac benefit from bypass surgery.Conclusions: Our results provide an atrial myocardium-focused insight into IHD signature RNAs. The specific gene expression changes characterized here, pave the way for future disease mechanism-based identification of biomarkers for early detection and treatment of IHD.

Tertiary Prevention of Ischemic Heart Disease: Post Coronary Artery Bypass Surgery

2015 ◽  
Vol 2 (4) ◽  
pp. 192-197 ◽  
Author(s):  
Shibban K Kaul ◽  
Archit Pankaj Patel ◽  
Jayant N Karbhase ◽  
Rajiv Kumar Srivastava ◽  
Sameer Sudhirchandra Kadam ◽  
...  
Keyword(s):  
Heart Disease ◽  
Coronary Artery ◽  
Ischemic Heart Disease ◽  
Coronary Artery Bypass ◽  
Coronary Artery Bypass Surgery ◽  
Bypass Surgery ◽  
Artery Bypass ◽  
Tertiary Prevention ◽  
Ischemic Heart

scholarly journals The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting

Kardiologiia ◽  
2019 ◽  
Vol 59 (6) ◽  
pp. 12-17
Author(s):  
O. L. Barbarash ◽  
V. V. Kashtalap ◽  
M. V. Zykov ◽  
O. N. Hryachkova ◽  
I. A. Shibanova
Keyword(s):  
Heart Disease ◽  
Drug Therapy ◽  
Coronary Artery ◽  
Ischemic Heart Disease ◽  
Coronary Artery Bypass ◽  
Bypass Surgery ◽  
Artery Bypass ◽  
Coronary Bypass ◽  
Ischemic Heart

Purpose: to assess drug therapy and achievement of target parameters of treatment in patients with ischemic heart disease (IHD) during 3–5 years of follow-up aſter coronary bypass surgery.Materials and methods. From the initial sample of the coronary bypass surgery registry (n=680) we selected for this study 111 men (mean age 61 [55; 65] years) hospitalized in 2011 with clinical picture of IHD for coronary artery bypass graſting (CABG).Results. Mean duration of follow-up was 4.2 years. Mortality was 11.7 % (n=13), 11 deaths were cardiovascular, 2 – from unknown causes. End points defined as repeat hospitalizations and IHD progression were registered in 18 of 98 patients (18.4 %). Only in 25 % of patients during 3–5 years of observation aſter CABG there were no clinical signs of angina. Five patients (5.1 %) developed new type 2 diabetes. Drug therapy: 80 patients (81.6 %) received acetylsalicylic acid, 60 (61.2 %) – angiotensin converting enzyme inhibitors, 80 (81.6 %) – β-adrenoblockers. Eighty-one men (82.6 %) received statins, but only 20 of 98 re-examined patients (20.4 %) took high doses. Target levels of low density lipoprotein cholesterolConclusion. Data of clinical practice illustrate insufficient quality of basic and antianginal therapy in patients with IHD aſter CABG. Indicators of control of angina, heart rate, achievement of target levels of parameters of lipid metabolism remain unsatisfactory.

Echocardiographic Assessment of Juxtaposition of the Right Atrial Appendage in Children with Congenital Heart Disease

2010 ◽  
Vol 27 (7) ◽  
pp. 878-884 ◽  
Author(s):  
Yu-Qi Zhang ◽  
Zhi-Qing Yu ◽  
Shu-Wen Zhong ◽  
Lan-Ping Wu ◽  
Guo-Zhen Chen ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Atrial Appendage ◽  
Right Atrial ◽  
Echocardiographic Assessment ◽  
Right Atrial Appendage ◽  
The Right

scholarly journals Epicardial Transplantation of Autologous Cardiac Micrografts During Coronary Artery Bypass Surgery

2021 ◽  
Vol 8 ◽  
Author(s):  
Annu Nummi ◽  
Severi Mulari ◽  
Juhani A. Stewart ◽  
Sari Kivistö ◽  
Kari Teittinen ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass ◽  
Outcome Measures ◽  
Coronary Artery Bypass Surgery ◽  
Bypass Surgery ◽  
Artery Bypass ◽  
Left Ventricular ◽  
Atrial Appendage ◽  
Right Atrial ◽  
Cabg Surgery

Background: Cardio-regenerative cell therapies offer additional biologic support to coronary artery bypass surgery (CABG) and are aimed at functionally repairing the myocardium that suffers from or is damaged by ischemia. This non-randomized open-label study assessed the safety and feasibility of epicardial transplantation of atrial appendage micrografts (AAMs) in patients undergoing CABG surgery.Methods: Twelve consecutive patients destined for CABG surgery were included in the study. Six patients received AAMs during their operation and six patients were CABG-operated without AAMs transplantation. Data from 30 elective CABG patients was collected for a center- and time-matched control group. The AAMs were processed during the operation from a biopsy collected from the right atrial appendage. They were delivered epicardially onto the infarct scar site identified in preoperative late gadolinium enhancement cardiac magnetic resonance imaging (CMRI). The primary outcome measures at the 6-month follow-up were (i) patient safety in terms of hemodynamic and cardiac function over time and (ii) feasibility of therapy administration in a clinical setting. Secondary outcome measures were left ventricular wall thickness, change in myocardial scar tissue volume, changes in left ventricular ejection fraction, plasma concentrations of N-terminal pro-B-type natriuretic peptide levels, NYHA class, number of days in hospital and changes in the quality of life.Results: Epicardial transplantation of AAMs was safe and feasible to be performed during CABG surgery. CMRI demonstrated an increase in viable cardiac tissue at the infarct site in patients receiving AAMs treatment.Conclusions and Relevance: Transplantation of AAMs shows good clinical applicability as performed during cardiac surgery, shows initial therapeutic effect on the myocardium and has the potential to serve as a delivery platform for cardiac gene therapies.Trial Registration:ClinicalTrials.gov, identifier: NCT02672163.

Sign in / Sign up

Export Citation Format

Share Document